Literature DB >> 19473234

Antagonism of serotonergic 5-HT2A/2C receptors: mutual improvement of sleep, cognition and mood?

H-P Landolt1, R Wehrle.   

Abstract

Serotonin [5-hydroxytryptamine (5-HT)] and 5-HT receptors are involved in sleep and in waking functions such as cognition and mood. Animal and human studies support a particular role for the 5-HT(2A) receptor in sleep, which has led to renewed interest in this receptor subtype as a target for the development of novel pharmacological agents to treat insomnia. Focusing primarily on findings in healthy human volunteers, a review of the available data suggests that antagonistic interaction with 5-HT(2A) receptors (and possibly also 5-HT(2C) receptors) prolongs the duration of slow wave sleep and enhances low-frequency (< 7 Hz) activity in the sleep electroencephalogram (EEG), a widely accepted marker of sleep intensity. Despite certain differences, the changes in sleep and the sleep EEG appear to be remarkably similar to those of physiologically more intense sleep after sleep deprivation. It is currently unclear whether these changes in sleep are associated with improved vigilance, cognition and mood during wakefulness. While drug-induced interaction with sleep must be interpreted cautiously, too few studies are available to provide a clear answer to this question. Moreover, functional relationships between sleep and waking functions may differ between healthy controls and patients with sleep disorders. A multimodal approach investigating subjective and objective aspects of sleep and wakefulness provides a promising research avenue for shedding light on the complex relationships among 5-HT(2A/2C) receptor-mediated effects on sleep, the sleep EEG, cognition and mood in health and various diseases associated with disturbed sleep and waking functions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19473234     DOI: 10.1111/j.1460-9568.2009.06718.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  29 in total

Review 1.  Drug-induced sleep: theoretical and practical considerations.

Authors:  Jeffrey M Ellenbogen; Edward F Pace-Schott
Journal:  Pflugers Arch       Date:  2011-09-28       Impact factor: 3.657

2.  Melatonin in aging and disease -multiple consequences of reduced secretion, options and limits of treatment.

Authors:  Rüdiger Hardeland
Journal:  Aging Dis       Date:  2011-02-10       Impact factor: 6.745

3.  Assessment of adverse effects of neurotropic drugs in monkeys with the "drug effects on the nervous system" (DENS) scale.

Authors:  Subramaniam Uthayathas; Christopher L Shaffer; Frank S Menniti; Christopher J Schmidt; Stella M Papa
Journal:  J Neurosci Methods       Date:  2013-02-16       Impact factor: 2.390

Review 4.  Update on melatonin receptors: IUPHAR Review 20.

Authors:  Ralf Jockers; Philippe Delagrange; Margarita L Dubocovich; Regina P Markus; Nicolas Renault; Gianluca Tosini; Erika Cecon; Darius P Zlotos
Journal:  Br J Pharmacol       Date:  2016-08-08       Impact factor: 8.739

Review 5.  Sleep as a Therapeutic Target in the Aging Brain.

Authors:  Thierno M Bah; James Goodman; Jeffrey J Iliff
Journal:  Neurotherapeutics       Date:  2019-07       Impact factor: 7.620

6.  [Disturbances of slow-wave sleep and psychiatric disorders].

Authors:  J P Doerr; V Hirscher; D Riemann; U Voderholzer
Journal:  Nervenarzt       Date:  2010-03       Impact factor: 1.214

Review 7.  Halogenated indole alkaloids from marine invertebrates.

Authors:  Patrícia Mendonça Pauletti; Lucas Silva Cintra; Caio Guedes Braguine; Ademar Alves da Silva Filho; Márcio Luís Andrade E Silva; Wilson Roberto Cunha; Ana Helena Januário
Journal:  Mar Drugs       Date:  2010-04-28       Impact factor: 5.118

8.  Novel Bivalent 5-HT2A Receptor Antagonists Exhibit High Affinity and Potency in Vitro and Efficacy in Vivo.

Authors:  Claudia A Soto; Matthew J Shashack; Robert G Fox; Marcy J Bubar; Kenner C Rice; Cheryl S Watson; Kathryn A Cunningham; Scott R Gilbertson; Noelle C Anastasio
Journal:  ACS Chem Neurosci       Date:  2017-11-21       Impact factor: 4.418

9.  Sleep deprivation increases cerebral serotonin 2A receptor binding in humans.

Authors:  David Elmenhorst; Tina Kroll; Andreas Matusch; Andreas Bauer
Journal:  Sleep       Date:  2012-12-01       Impact factor: 5.849

10.  Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults.

Authors:  Robert H Howland
Journal:  Neuropsychiatr Dis Treat       Date:  2009-11-16       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.